Multiple Myeloma

An overview of the study design, efficacy, and safety findings of the MAIA trial.

Dr Nisha Joseph presents the case of a woman with transplant-ineligible multiple myeloma and discusses considerations when choosing frontline treatment regimens.

Shared insight on the GMMG-HD7 study, which utilized a frontline isatuximab-containing quadruplet regimen in patients with newly diagnosed multiple myeloma.

Expert perspectives on frontline daratumumab-containing quadruplet regimens in the context of recent clinical trials in newly diagnosed multiple myeloma.

Drs Ajay Nooka and Jonathan Kaufman discuss maintenance and consolidation treatment strategies for transplant eligible multiple myeloma.

Experts discuss how they select a treatment regimen for a newly diagnosed multiple myeloma patient, and how they measure a successful treatment response.

Minimal residual disease status 3 months and 6 months following autologous stem-cell transplant could be predictive of progression-free survival and overall survival outcomes in multiple myeloma.

Nina Shah, MD, spoke about her key takeaways from a sub-analysis of the phase 2 KarMMa trial assessing correlates of complete response among those treated with idecabtagene vicleucel in relapsed/refractory multiple myeloma.

Nina Shah, MD, spoke about analyzing correlates of complete response in patients with relapsed/refractory multiple myeloma who were treated with idecabtagene vicleucel.

Investigators have identified an association between the diagnosis and care of older patients with multiple myeloma and substantial financial burden on Medicare.

Response to idecabtagene vicleucel for patients with pretreated multiple myeloma did not appear to be influenced by baseline body mass index.

A review of the study design and results of two clinical trials researching quadruplet therapies for newly diagnosed multiple myeloma presented at ASH 2021.

Investigators observed low enrollment of Black patients on CAR T-cell therapy clinical trials that supported FDA decisions in hematologic malignancies, especially in multiple myeloma.

An overview of the currently available frontline treatment options for transplant-eligible multiple myeloma.

At the 2022 Tandem Meetings, Nina Shah, MD, spoke about key findings from the phase 2 KarMMa trial that used idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma.

The phase 2 KarMMA trial showed that certain characteristics were potentially linked to complete responses in patients with multiple myeloma.

Findings from the phase 2 CARITUDE-2 trial which investigated ciltacabtagene autoleucel in patients with multiple myeloma indicated that a single infusion produced deep responses.

Ixazomib did not appear to be an effective replacement for carfilzomib or bortezomib in combination regimens containing the 2 proteosome inhibitors in patients with relapsed/refractory multiple myeloma.

A look at the unmet needs and future directions of multiple myeloma treatment.

Oncologists highlight novel agents currently being investigated for the treatment of relapsed/refractory multiple myeloma.

A real-world study found patients with relapsed/refractory multiple myeloma who were triple-class exposed had higher healthcare costs and unmet treatment needs.

Key takeaways from the CARTITUDE-1 study and the KarMMA study evaluating CAR T-cell therapies for relapsed/refractory multiple myeloma.

An overview of BCMA-targeting bispecific agents in development for multiple myeloma, including talquetamab and teclistamab.

A panel of doctors discuss the available treatment options for early and late relapsed multiple myeloma, including approved novel BCMA-targeting agents.

A look at the patient outcomes with daratumumab use in the frontline vs second-line setting in patients with transplant-ineligible multiple myeloma, and the pros and cons of subcutaneous vs intravenous daratumumab.

Patients with multiple myeloma and high-risk cytogenetics may benefit from treatment with high-dose therapy consolidation compared with delaying this approach.

Experts share their excitement for upcoming PFS trial data to be presented on the combination of ixazomib, pomalidomide, and dexamethasone in multiple myeloma.

Expert perspectives on the triplet combination of ixazomib, pomalidomide, and dexamethasone in multiple myeloma presented at the 2021 ASH [American Society of Hematology] Annual Meeting.

Continuing their discussion on the management of multiple myeloma, experts Paul Richardson, MD, and Cristina Gasparetto, MD, consider the value of minimal residual disease as a marker.

Investigators spoke to the disparities that are present in multiple myeloma and possible causes such as socioeconomic factors.